Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686634 · ClinicalTrials.gov registry record · Phase 4
Sitagliptin in Combination With Metformin and Sulfonylurea
A Phase 4 study, sponsored by Charles Drew University of Medicine and Science.
- Completed
- Registry status
- Phase 4
- Development phase
- 108
- Enrollment target
NCT00686634 is a Phase 4 study that has completed, run by Charles Drew University of Medicine and Science. The registered enrollment target is 108 participants.
The verdict
NCT00686634, a Phase 4 study, has completed, sponsored by Charles Drew University of Medicine and Science.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 108 participants
- Enrollment target
Study Summary
This study will compare the effect of a new oral agent for type 2 diabetes, sitagliptin, in comparison to thiazolidinediones as the third-line oral agent, in patients with type 2 diabetes mellitus.
Interventions
- DRUG Sitagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00686634
The ClinicalTrials.gov registry entry for NCT00686634 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Charles Drew University of Medicine and Science, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sitagliptin is the first listed.
NCT00686634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00686634 about?
NCT00686634 is a clinical study titled "Sitagliptin in Combination With Metformin and Sulfonylurea". This study will compare the effect of a new oral agent for type 2 diabetes, sitagliptin, in comparison to thiazolidinediones as the third-line oral agent, in patients with type 2 diabetes mellitus.
What is the current status of trial NCT00686634?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 108 participants. The study started on 2008-01. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00686634?
The interventions under investigation include: Sitagliptin (DRUG).
Who is sponsoring clinical trial NCT00686634?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.